CA2273064C - Novel processes for amplifying nucleic acid, post-termination labeling process for nucleic acid sequencing and producing nucleic acid having decreased thermodynamic stability - Google Patents
Novel processes for amplifying nucleic acid, post-termination labeling process for nucleic acid sequencing and producing nucleic acid having decreased thermodynamic stability Download PDFInfo
- Publication number
- CA2273064C CA2273064C CA002273064A CA2273064A CA2273064C CA 2273064 C CA2273064 C CA 2273064C CA 002273064 A CA002273064 A CA 002273064A CA 2273064 A CA2273064 A CA 2273064A CA 2273064 C CA2273064 C CA 2273064C
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- segment
- primer
- acid sequence
- template
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 380
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 238
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 238
- 238000000034 method Methods 0.000 title claims abstract description 185
- 230000008569 process Effects 0.000 title claims abstract description 129
- 238000002372 labelling Methods 0.000 title abstract description 17
- 238000012163 sequencing technique Methods 0.000 title abstract description 15
- 230000003247 decreasing effect Effects 0.000 title abstract description 11
- 230000000295 complement effect Effects 0.000 claims abstract description 146
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 126
- 230000003321 amplification Effects 0.000 claims abstract description 117
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 117
- 125000003729 nucleotide group Chemical group 0.000 claims description 185
- 238000009739 binding Methods 0.000 claims description 104
- 230000027455 binding Effects 0.000 claims description 104
- 230000015572 biosynthetic process Effects 0.000 claims description 91
- 230000001419 dependent effect Effects 0.000 claims description 77
- 102000004190 Enzymes Human genes 0.000 claims description 60
- 108090000790 Enzymes Proteins 0.000 claims description 60
- 239000002773 nucleotide Substances 0.000 claims description 49
- 239000000872 buffer Substances 0.000 claims description 47
- 239000000758 substrate Substances 0.000 claims description 38
- 230000001351 cycling effect Effects 0.000 claims description 35
- 230000000379 polymerizing effect Effects 0.000 claims description 26
- 108091008146 restriction endonucleases Proteins 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 11
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 10
- 125000003636 chemical group Chemical group 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 10
- 230000002255 enzymatic effect Effects 0.000 claims description 6
- 239000000138 intercalating agent Substances 0.000 claims description 6
- 101710163270 Nuclease Proteins 0.000 claims description 5
- 108010042407 Endonucleases Proteins 0.000 claims description 3
- 102000004533 Endonucleases Human genes 0.000 claims description 3
- 238000010306 acid treatment Methods 0.000 claims description 2
- 238000000527 sonication Methods 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 abstract description 27
- 238000001514 detection method Methods 0.000 abstract description 11
- 229920000642 polymer Polymers 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 description 152
- 239000000047 product Substances 0.000 description 80
- 108020004414 DNA Proteins 0.000 description 72
- 238000003786 synthesis reaction Methods 0.000 description 65
- 238000003752 polymerase chain reaction Methods 0.000 description 52
- 238000004925 denaturation Methods 0.000 description 31
- 230000036425 denaturation Effects 0.000 description 31
- 238000000926 separation method Methods 0.000 description 28
- 239000000499 gel Substances 0.000 description 26
- 238000003556 assay Methods 0.000 description 23
- 108091093088 Amplicon Proteins 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 22
- 238000010348 incorporation Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 230000037452 priming Effects 0.000 description 18
- 241000700721 Hepatitis B virus Species 0.000 description 17
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 238000000137 annealing Methods 0.000 description 11
- 239000012467 final product Substances 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- -1 carboxy dUTP Chemical compound 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 102100034343 Integrase Human genes 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 239000003623 enhancer Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 238000011901 isothermal amplification Methods 0.000 description 9
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
- 238000006073 displacement reaction Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 description 6
- 108010006785 Taq Polymerase Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 101000733752 Homo sapiens Retroviral-like aspartic protease 1 Proteins 0.000 description 5
- 102100033717 Retroviral-like aspartic protease 1 Human genes 0.000 description 5
- 108010020713 Tth polymerase Proteins 0.000 description 5
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 5
- OTXOHOIOFJSIFX-POYBYMJQSA-N [[(2s,5r)-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)O)CC[C@@H]1N1C(=O)NC(=O)C=C1 OTXOHOIOFJSIFX-POYBYMJQSA-N 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical group [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 4
- 239000005546 dideoxynucleotide Substances 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- UFJPAQSLHAGEBL-RRKCRQDMSA-N dITP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1 UFJPAQSLHAGEBL-RRKCRQDMSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000027832 depurination Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000010223 real-time analysis Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920002466 Dynel Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 101150104425 T4 gene Proteins 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- NCGWKCHAJOUDHQ-UHFFFAOYSA-N n,n-diethylethanamine;formic acid Chemical compound OC=O.OC=O.CCN(CC)CC NCGWKCHAJOUDHQ-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002475018A CA2475018C (en) | 1998-06-24 | 1999-06-15 | Novel processes for amplifying nucleic acid, post-termination labeling process for nucleic acid sequencing and producing nucleic acid having decreased thermodynamic stability |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/104,067 US6743605B1 (en) | 1998-06-24 | 1998-06-24 | Linear amplification of specific nucleic acid sequences |
| US09/104,067 | 1998-06-24 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002475018A Division CA2475018C (en) | 1998-06-24 | 1999-06-15 | Novel processes for amplifying nucleic acid, post-termination labeling process for nucleic acid sequencing and producing nucleic acid having decreased thermodynamic stability |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2273064A1 CA2273064A1 (en) | 1999-12-24 |
| CA2273064C true CA2273064C (en) | 2008-04-01 |
Family
ID=22298492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002273064A Expired - Lifetime CA2273064C (en) | 1998-06-24 | 1999-06-15 | Novel processes for amplifying nucleic acid, post-termination labeling process for nucleic acid sequencing and producing nucleic acid having decreased thermodynamic stability |
Country Status (6)
| Country | Link |
|---|---|
| US (11) | US6743605B1 (OSRAM) |
| EP (1) | EP0971039B1 (OSRAM) |
| JP (3) | JP2000037194A (OSRAM) |
| CA (1) | CA2273064C (OSRAM) |
| DE (1) | DE69943292D1 (OSRAM) |
| IL (1) | IL130477A (OSRAM) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994003624A1 (en) | 1992-08-04 | 1994-02-17 | Auerbach Jeffrey I | Methods for the isothermal amplification of nucleic acid molecules |
| US6261808B1 (en) | 1992-08-04 | 2001-07-17 | Replicon, Inc. | Amplification of nucleic acid molecules via circular replicons |
| GB9812768D0 (en) * | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
| US8445664B2 (en) | 1998-06-24 | 2013-05-21 | Enzo Diagnostics, Inc. | Kits for amplifying and detecting nucleic acid sequences |
| US6743605B1 (en) * | 1998-06-24 | 2004-06-01 | Enzo Life Sciences, Inc. | Linear amplification of specific nucleic acid sequences |
| JP3974441B2 (ja) * | 1998-11-09 | 2007-09-12 | 栄研化学株式会社 | 核酸の合成方法 |
| WO2000028082A1 (fr) | 1998-11-09 | 2000-05-18 | Eiken Kagaku Kabushiki Kaisha | Procede de synthese d'acide nucleique |
| US6692918B2 (en) | 1999-09-13 | 2004-02-17 | Nugen Technologies, Inc. | Methods and compositions for linear isothermal amplification of polynucleotide sequences |
| DE60025840T2 (de) | 1999-11-08 | 2006-07-27 | Eiken Kagaku K.K. | Methode zum nachweis von variationen oder polymorphismen |
| JP4721603B2 (ja) * | 1999-11-08 | 2011-07-13 | 栄研化学株式会社 | 変異および／または多型の検出方法 |
| AU2001244677A1 (en) | 2000-04-07 | 2001-10-23 | Eiken Kagaku Kabushiki Kaisha | Method of amplifying nucleic acid by using double-stranded nucleic acid as template |
| JP2001309785A (ja) * | 2000-05-01 | 2001-11-06 | Eiken Chem Co Ltd | 遺伝子配列間の相違検出方法 |
| US7846733B2 (en) | 2000-06-26 | 2010-12-07 | Nugen Technologies, Inc. | Methods and compositions for transcription-based nucleic acid amplification |
| ATE455186T1 (de) | 2000-06-26 | 2010-01-15 | Nugen Technologies Inc | Methoden und zusammensetzungen zur auf transkription basierenden vervielfältigung von nukleinsäuren |
| WO2002024902A1 (en) | 2000-09-19 | 2002-03-28 | Eiken Kagaku Kabushiki Kaisha | Method of synthesizing polynucleotide |
| EP1427847B1 (en) | 2000-12-13 | 2010-07-28 | Nugen Technologies, Inc. | Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof |
| BR0205268A (pt) | 2001-03-09 | 2004-11-30 | Nugen Technologies Inc | Processos e composições para a mplificação de sequências de rna |
| CA2439074A1 (en) * | 2001-03-09 | 2002-09-19 | Nugen Technologies, Inc. | Methods and compositions for amplification of rna sequences |
| US20040161741A1 (en) | 2001-06-30 | 2004-08-19 | Elazar Rabani | Novel compositions and processes for analyte detection, quantification and amplification |
| US9777312B2 (en) | 2001-06-30 | 2017-10-03 | Enzo Life Sciences, Inc. | Dual polarity analysis of nucleic acids |
| US9261460B2 (en) | 2002-03-12 | 2016-02-16 | Enzo Life Sciences, Inc. | Real-time nucleic acid detection processes and compositions |
| JP2005052002A (ja) * | 2001-07-06 | 2005-03-03 | Wakunaga Pharmaceut Co Ltd | 非環状核酸断片の増幅方法 |
| US20110151438A9 (en) | 2001-11-19 | 2011-06-23 | Affymetrix, Inc. | Methods of Analysis of Methylation |
| WO2003044216A2 (en) | 2001-11-19 | 2003-05-30 | Parallele Bioscience, Inc. | Multiplex oligonucleotide addition and target amplification |
| US9353405B2 (en) | 2002-03-12 | 2016-05-31 | Enzo Life Sciences, Inc. | Optimized real time nucleic acid detection processes |
| US6815167B2 (en) | 2002-04-25 | 2004-11-09 | Geneohm Sciences | Amplification of DNA to produce single-stranded product of defined sequence and length |
| EP2292801B1 (en) | 2002-06-14 | 2018-08-08 | Gen-Probe Incorporated | Compositions and methods for detecting hepatitis b virus |
| GB0218215D0 (en) * | 2002-08-06 | 2002-09-11 | Tepnel Medical Ltd | Amplification of nucleic acids |
| TW200413527A (en) | 2002-10-29 | 2004-08-01 | Riken | Amplification of nucleic acid |
| EP1613778B1 (en) * | 2003-04-14 | 2014-11-26 | Nugen Technologies, Inc. | Global amplification using a randomly primed composite primer |
| EP1712618B1 (en) * | 2003-12-25 | 2014-06-04 | Riken | Method of amplifying nucleic acid and method of detecting mutated nucleic acid using the same |
| US7575863B2 (en) | 2004-05-28 | 2009-08-18 | Applied Biosystems, Llc | Methods, compositions, and kits comprising linker probes for quantifying polynucleotides |
| CA2476030A1 (en) * | 2004-06-09 | 2005-12-09 | Wilsun Xu | A power signaling based technique for detecting islanding conditions in electric power distribution systems |
| US8124334B2 (en) * | 2004-07-06 | 2012-02-28 | Enzo Biochem, Inc. | Selective detection of oncogenic HPV |
| WO2006034387A1 (en) * | 2004-09-21 | 2006-03-30 | Applera Corporation | TWO-COLOR REAL-TIME/END-POINT QUANTITATION OF MICRORNAS (miRNAs) |
| EP1696040A1 (en) * | 2005-02-28 | 2006-08-30 | Eurofins Viralliance, Inc. | Method of genotyping and phenotyping hepatitis B viruses resistant to antiviral molecules |
| EP1871896B1 (en) * | 2005-04-12 | 2015-06-03 | Olink AB | Circle probes and their use in the identification of biomolecules |
| EP1871897B1 (en) | 2005-04-12 | 2010-09-29 | Olink AB | Methods for production of oligonucleotides |
| NZ620811A (en) | 2005-05-09 | 2015-09-25 | Theranos Inc | Point-of-care fluidic systems and uses thereof |
| US20070054301A1 (en) * | 2005-09-06 | 2007-03-08 | Gen-Probe Incorporated | Methods, compositions and kits for isothermal amplification of nucleic acids |
| WO2007030759A2 (en) | 2005-09-07 | 2007-03-15 | Nugen Technologies, Inc. | Improved nucleic acid amplification procedure |
| EP3263117A1 (en) * | 2005-11-28 | 2018-01-03 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| JP4580875B2 (ja) * | 2006-01-20 | 2010-11-17 | 株式会社東芝 | 核酸検出法のためのプライマーの設計方法 |
| US11287421B2 (en) | 2006-03-24 | 2022-03-29 | Labrador Diagnostics Llc | Systems and methods of sample processing and fluid control in a fluidic system |
| US8007999B2 (en) | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
| US7833716B2 (en) | 2006-06-06 | 2010-11-16 | Gen-Probe Incorporated | Tagged oligonucleotides and their use in nucleic acid amplification methods |
| US7501254B2 (en) | 2006-07-20 | 2009-03-10 | Ghc Technologies, Inc. | Methods and compositions for amplification and capture of nucleic acid sequences |
| US8012744B2 (en) | 2006-10-13 | 2011-09-06 | Theranos, Inc. | Reducing optical interference in a fluidic device |
| US20080113391A1 (en) | 2006-11-14 | 2008-05-15 | Ian Gibbons | Detection and quantification of analytes in bodily fluids |
| AU2008206221A1 (en) * | 2007-01-17 | 2008-07-24 | Meridian Bioscience, Inc. | Stable reagents and kits useful in loop-mediated isothermal amplification (LAMP) |
| US8158430B1 (en) | 2007-08-06 | 2012-04-17 | Theranos, Inc. | Systems and methods of fluidic sample processing |
| MX352987B (es) | 2007-10-02 | 2017-12-15 | Theranos Ip Co Llc | Dispositivos modulares de punto de cuidado y usos de los mismos. |
| US8420323B2 (en) * | 2007-11-14 | 2013-04-16 | Fujifilm Corporation | Nucleic acid amplification method |
| US20090162845A1 (en) | 2007-12-20 | 2009-06-25 | Elazar Rabbani | Affinity tag nucleic acid and protein compositions, and processes for using same |
| US8034568B2 (en) | 2008-02-12 | 2011-10-11 | Nugen Technologies, Inc. | Isothermal nucleic acid amplification methods and compositions |
| US20090215050A1 (en) * | 2008-02-22 | 2009-08-27 | Robert Delmar Jenison | Systems and methods for point-of-care amplification and detection of polynucleotides |
| WO2009117698A2 (en) | 2008-03-21 | 2009-09-24 | Nugen Technologies, Inc. | Methods of rna amplification in the presence of dna |
| GB0820927D0 (en) | 2008-11-14 | 2008-12-24 | Isis Innovation | Method |
| AU2010209528B2 (en) | 2009-01-30 | 2015-10-01 | Oxford Nanopore Technologies Limited | Adaptors for nucleic acid constructs in transmembrane sequencing |
| GB0905140D0 (en) | 2009-03-25 | 2009-05-06 | Isis Innovation | Method |
| US9393564B2 (en) | 2009-03-30 | 2016-07-19 | Ibis Biosciences, Inc. | Bioagent detection systems, devices, and methods |
| EP2272980A1 (en) * | 2009-07-09 | 2011-01-12 | Bioesplora SRL | Molecular probes for target nucleic acid detection and quantification |
| US9416409B2 (en) | 2009-07-31 | 2016-08-16 | Ibis Biosciences, Inc. | Capture primers and capture sequence linked solid supports for molecular diagnostic tests |
| MY165876A (en) | 2009-10-19 | 2018-05-18 | Theranos Inc | Integrated health data capture and analysis system |
| AU2010321576A1 (en) | 2009-11-23 | 2012-06-07 | Swift Biosciences, Inc. | Devices to extend single stranded target molecules |
| CA2825196C (en) | 2011-01-21 | 2021-01-05 | Theranos, Inc. | Systems and methods for sample use maximization |
| WO2013014451A1 (en) | 2011-07-25 | 2013-01-31 | Oxford Nanopore Technologies Limited | Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores |
| US9109226B2 (en) * | 2011-09-01 | 2015-08-18 | New England Biolabs, Inc. | Synthetic nucleic acids for polymerization reactions |
| US9416153B2 (en) | 2011-10-11 | 2016-08-16 | Enzo Life Sciences, Inc. | Fluorescent dyes |
| US9970061B2 (en) | 2011-12-27 | 2018-05-15 | Ibis Biosciences, Inc. | Bioagent detection oligonucleotides |
| EP2798089B1 (en) | 2011-12-30 | 2018-05-23 | Bio-rad Laboratories, Inc. | Methods and compositions for performing nucleic acid amplification reactions |
| EP2802666B1 (en) | 2012-01-13 | 2018-09-19 | Data2Bio | Genotyping by next-generation sequencing |
| WO2013153359A1 (en) | 2012-04-10 | 2013-10-17 | Oxford Nanopore Technologies Limited | Mutant lysenin pores |
| EP2875154B1 (en) | 2012-07-19 | 2017-08-23 | Oxford Nanopore Technologies Limited | SSB method for characterising a nucleic acid |
| EP3511424B1 (en) | 2012-08-03 | 2023-10-18 | University Of Washington Through Its Center For Commercialization | Compositions and methods for improving nanopore sequencing |
| WO2014110127A1 (en) | 2013-01-08 | 2014-07-17 | Enzo Biochem, Inc. | Diagnosis and treatment of viral diseases |
| US9617607B2 (en) | 2013-01-08 | 2017-04-11 | Enzo Biochem, Inc. | Diagnosis and treatment of viral diseases |
| KR102168813B1 (ko) | 2013-03-08 | 2020-10-22 | 옥스포드 나노포어 테크놀로지즈 리미티드 | 효소 정지 방법 |
| GB201314695D0 (en) | 2013-08-16 | 2013-10-02 | Oxford Nanopore Tech Ltd | Method |
| CA2903874C (en) | 2013-03-15 | 2024-02-20 | Theranos, Inc. | Nucleic acid amplification |
| SG11201507272RA (en) | 2013-03-15 | 2015-10-29 | Theranos Inc | Nuclei acid amplification |
| EP3587592A1 (en) | 2013-03-15 | 2020-01-01 | Theranos IP Company, LLC | Nucleic acid amplification |
| US10450595B2 (en) | 2013-03-15 | 2019-10-22 | Theranos Ip Company, Llc | Nucleic acid amplification |
| GB201313477D0 (en) | 2013-07-29 | 2013-09-11 | Univ Leuven Kath | Nanopore biosensors for detection of proteins and nucleic acids |
| BR112016004994A2 (pt) | 2013-09-06 | 2021-05-11 | Theranos Ip Company, Llc | Sistemas e métodos para detectar doenças infecciosas |
| CN106103741B (zh) | 2014-01-22 | 2020-03-13 | 牛津纳米孔技术公司 | 将一个或多个多核苷酸结合蛋白连接到靶多核苷酸的方法 |
| GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
| WO2015166276A1 (en) | 2014-05-02 | 2015-11-05 | Oxford Nanopore Technologies Limited | Method of improving the movement of a target polynucleotide with respect to a transmembrane pore |
| US10093918B2 (en) | 2014-06-04 | 2018-10-09 | Lucigen Corporation | Sample collection and analysis devices |
| US10364458B2 (en) | 2014-07-16 | 2019-07-30 | Tangen Biosciences, Inc. | Isothermal methods for amplifying nucleic acid samples |
| EP4053150A1 (en) | 2014-09-01 | 2022-09-07 | Vib Vzw | Mutant csgg pores |
| CA2961209A1 (en) * | 2014-09-17 | 2016-03-24 | Theranos, Inc. | Diagnostic methods and compositions |
| US10266885B2 (en) | 2014-10-07 | 2019-04-23 | Oxford Nanopore Technologies Ltd. | Mutant pores |
| GB201418159D0 (en) | 2014-10-14 | 2014-11-26 | Oxford Nanopore Tech Ltd | Method |
| CN107208012B (zh) | 2014-11-03 | 2021-06-29 | 唐恩生物科学公司 | 用于细胞、孢子或病毒捕获和破碎的装置和方法 |
| GB201502809D0 (en) | 2015-02-19 | 2015-04-08 | Oxford Nanopore Tech Ltd | Mutant pore |
| GB201502810D0 (en) | 2015-02-19 | 2015-04-08 | Oxford Nanopore Tech Ltd | Method |
| EP3283887B1 (en) | 2015-04-14 | 2021-07-21 | Katholieke Universiteit Leuven | Nanopores with internal protein adaptors |
| CN109072295B (zh) | 2015-12-08 | 2022-05-31 | 鲁汶大学研究与发展中心 | 修饰的纳米孔，包含其的组合物及其应用 |
| US11766435B2 (en) * | 2016-02-18 | 2023-09-26 | Merck Sharp & Dohme Llc | N3-substituted iminopyrimidinones as antimalarial agents |
| EP3423486B1 (en) | 2016-03-02 | 2021-12-29 | Oxford Nanopore Technologies PLC | Mutant pore |
| CA3020203A1 (en) | 2016-04-06 | 2017-10-12 | Oxford Nanopore Technologies Limited | Mutant pore |
| GB201609220D0 (en) | 2016-05-25 | 2016-07-06 | Oxford Nanopore Tech Ltd | Method |
| EP4202439B1 (en) | 2016-06-09 | 2025-02-19 | The Regents of the University of California | Method of purifying and amplifying a nucleic acid |
| US10822648B1 (en) | 2016-07-29 | 2020-11-03 | Labrador Diagnostics Llc | Hybrid multi-step nucleic acid amplification |
| IL267836B2 (en) | 2017-01-04 | 2023-09-01 | Complete Genomics Inc | Stepwise sequence determination by unlabeled reversible terminations or natural nucleotides |
| GB201707122D0 (en) | 2017-05-04 | 2017-06-21 | Oxford Nanopore Tech Ltd | Pore |
| WO2018236918A1 (en) | 2017-06-20 | 2018-12-27 | Bio-Rad Laboratories, Inc. | MDA USING A BALL OLIGONUCLEOTIDE |
| CN117106037B (zh) | 2017-06-30 | 2025-07-25 | 弗拉芒区生物技术研究所 | 新颖蛋白孔 |
| GB201807793D0 (en) | 2018-05-14 | 2018-06-27 | Oxford Nanopore Tech Ltd | Method |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE265429C (OSRAM) | 1911-12-15 | 1913-10-10 | ||
| US4711955A (en) * | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| US5260433A (en) | 1982-06-23 | 1993-11-09 | Enzo Diagnostics, Inc. | Saccharide specific binding system labeled nucleotides |
| US5241060A (en) | 1982-06-23 | 1993-08-31 | Enzo Diagnostics, Inc. | Base moiety-labeled detectable nucleatide |
| US5171534A (en) | 1984-01-16 | 1992-12-15 | California Institute Of Technology | Automated DNA sequencing technique |
| US4707440A (en) | 1984-01-30 | 1987-11-17 | Enzo Biochem, Inc. | Nucleic acid hybridization assay and detectable molecules useful in such assay |
| US4729947A (en) | 1984-03-29 | 1988-03-08 | The Board Of Regents Of The University Of Nebraska | DNA sequencing |
| US5230781A (en) | 1984-03-29 | 1993-07-27 | Li-Cor, Inc. | Sequencing near infrared and infrared fluorescence labeled DNA for detecting using laser diodes |
| US5346603A (en) | 1984-03-29 | 1994-09-13 | The Board Of Regents Of The University Of Nebraska | DNA sequencing |
| US5360523A (en) | 1984-03-29 | 1994-11-01 | Li-Cor, Inc. | DNA sequencing |
| US4749647A (en) * | 1984-06-22 | 1988-06-07 | Genetic Systems Corporation | Polymerization-induced separation assay using recognition pairs |
| GB8421967D0 (en) * | 1984-08-30 | 1984-10-03 | Hickory Springs Mfg Co | Polyurethane foams |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5093232A (en) * | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
| JP3293820B2 (ja) | 1985-12-13 | 2002-06-17 | エンゾ− バイオケム インコ−ポレイテツド | 標的ポリヌクレオチドにハイブリツド形成するための新規な一工程方法とポリヌクレオチド化合物 |
| CA1340806C (en) | 1986-07-02 | 1999-11-02 | James Merrill Prober | Method, system and reagents for dna sequencing |
| US5047519A (en) | 1986-07-02 | 1991-09-10 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
| US5032570A (en) | 1987-08-04 | 1991-07-16 | Hitachi Metals, Ltd. | Method for producing ceramic superconducting material using intermediate products |
| DD265429A1 (de) * | 1987-09-30 | 1989-03-01 | Adl Inst Phytopathologie | Verfahren zur nichtradioaktiven markierung von polynukleotiden |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| US5260428A (en) * | 1988-07-11 | 1993-11-09 | Boehringer Mannheim Gmbh | Agent for the detection of substances with hydrolase activity |
| US5508178A (en) | 1989-01-19 | 1996-04-16 | Rose; Samuel | Nucleic acid amplification using single primer |
| US5503975A (en) * | 1989-03-01 | 1996-04-02 | City Of Hope | Mechanism based inhibitors of DNA methyltransferase |
| JPH0750041Y2 (ja) | 1990-01-17 | 1995-11-15 | 大同特殊鋼株式会社 | 連続鋳造設備におけるタンディッシュ交換装置 |
| WO1992000989A1 (en) | 1990-07-10 | 1992-01-23 | Imperial Chemical Industries Plc | Non-isotopic nucleic acid labelling method |
| US5595891A (en) | 1990-07-19 | 1997-01-21 | Behringwerke Ag | Method for producing a polynucleotide for use in single primer amplification |
| US5439793A (en) | 1990-07-19 | 1995-08-08 | Syntex (U.S.A.) Inc. | Method for producing a polynucleotide having an intramolecularly base-paired structure |
| US5518900A (en) * | 1993-01-15 | 1996-05-21 | Molecular Tool, Inc. | Method for generating single-stranded DNA molecules |
| US5569582A (en) * | 1991-07-15 | 1996-10-29 | Institute Of Molecular Biology & Technology | Rapid amplification and detection of nucleic acids |
| US5714323A (en) * | 1991-08-30 | 1998-02-03 | The University Of Medecine And Dentistry Of New Jersey | Over expression of single-stranded molecules |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US5612199A (en) | 1991-10-11 | 1997-03-18 | Behringwerke Ag | Method for producing a polynucleotide for use in single primer amplification |
| EP0656065A1 (en) | 1991-10-31 | 1995-06-07 | University Of Pittsburgh | Reverse dot blot hybridization using tandem head-to-tail monomers containing probes synthesized by staggered complementary primers |
| US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
| ZA929351B (en) * | 1991-12-11 | 1993-06-04 | Igen Inc | Electrochemiluminescent label for DNA assays. |
| FR2687679B1 (fr) * | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| US5462854A (en) | 1993-04-19 | 1995-10-31 | Beckman Instruments, Inc. | Inverse linkage oligonucleotides for chemical and enzymatic processes |
| US5470723A (en) | 1993-05-05 | 1995-11-28 | Becton, Dickinson And Company | Detection of mycobacteria by multiplex nucleic acid amplification |
| WO1995002690A1 (en) | 1993-07-13 | 1995-01-26 | Abbott Laboratories | Nucleotide sequences and process for amplifying and detection of hepatitis b virus |
| CA2105364A1 (en) * | 1993-09-01 | 1995-03-02 | Eric T. Kool | Stem-loop oligonucleotides containing parallel and antiparallel binding domains |
| DE4331670A1 (de) | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
| US5470184A (en) * | 1994-01-14 | 1995-11-28 | Chandler; Charles W. | Screw hole plug |
| US5462584A (en) | 1994-03-21 | 1995-10-31 | Gas Research Institute | Process for dehydrating natural gas |
| FR2721945B1 (fr) | 1994-07-04 | 1996-10-18 | David Fabrice | Accroissement genique, un procede d'amplicication genique isotherme et ses applications |
| FR2726277B1 (fr) | 1994-10-28 | 1996-12-27 | Bio Merieux | Oligonucleotide utilisable comme amorce dans une methode d'amplification basee sur une replication avec deplacement de brin |
| US5665545A (en) * | 1994-11-28 | 1997-09-09 | Akzo Nobel N.V. | Terminal repeat amplification method |
| US5798276A (en) * | 1995-06-07 | 1998-08-25 | Molecular Probes, Inc. | Reactive derivatives of sulforhodamine 101 with enhanced hydrolytic stability |
| AT402203B (de) | 1995-06-13 | 1997-03-25 | Himmler Gottfried Dipl Ing Dr | Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren |
| WO1997004131A1 (en) | 1995-07-21 | 1997-02-06 | Forsyth Dental Infirmary For Children | Single primer amplification of polynucleotide hairpins |
| US6114150A (en) * | 1995-11-29 | 2000-09-05 | Yale University | Amplification of nucleic acids |
| GB9609441D0 (en) | 1996-05-04 | 1996-07-10 | Zeneca Ltd | Process |
| US5821356A (en) | 1996-08-12 | 1998-10-13 | The Perkin Elmer Corporation | Propargylethoxyamino nucleotides |
| JPH10312826A (ja) | 1997-03-10 | 1998-11-24 | Sanyo Electric Co Ltd | 非水電解質電池及びその充電方法 |
| EP0973788A1 (en) | 1997-04-02 | 2000-01-26 | Amersham Pharmacia Biotech UK Limited | Tricyclic base analogues |
| GB9717061D0 (en) | 1997-08-13 | 1997-10-15 | Tepnel Medical Ltd | Amplification of nucleic acids |
| US6087099A (en) * | 1997-09-08 | 2000-07-11 | Myriad Genetics, Inc. | Method for sequencing both strands of a double stranded DNA in a single sequencing reaction |
| US6124120A (en) | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
| GB9810865D0 (en) | 1998-05-20 | 1998-07-22 | Zeneca Ltd | Nucleic acid sequence identification |
| US5991238A (en) | 1998-06-09 | 1999-11-23 | Western Atlas International, Inc. | Weighted backus filter method of combining dual sensor traces |
| GB9812768D0 (en) | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
| US6743605B1 (en) * | 1998-06-24 | 2004-06-01 | Enzo Life Sciences, Inc. | Linear amplification of specific nucleic acid sequences |
| WO2000028082A1 (fr) * | 1998-11-09 | 2000-05-18 | Eiken Kagaku Kabushiki Kaisha | Procede de synthese d'acide nucleique |
| US6114123A (en) | 1999-06-14 | 2000-09-05 | Incyte Pharmaceuticals, Inc. | Lipocalin family protein |
| DE60025840T2 (de) | 1999-11-08 | 2006-07-27 | Eiken Kagaku K.K. | Methode zum nachweis von variationen oder polymorphismen |
| BR0015382B1 (pt) | 1999-11-08 | 2014-04-29 | Eiken Chemical | Processos e kits para sintetizacao e amplificação do acido nucleico bem como, processos para detectar uma sequencia de nucleotideo alvo e de uma mutacao da dita sequencia |
-
1998
- 1998-06-24 US US09/104,067 patent/US6743605B1/en not_active Expired - Lifetime
-
1999
- 1999-06-14 IL IL13047799A patent/IL130477A/en not_active IP Right Cessation
- 1999-06-15 CA CA002273064A patent/CA2273064C/en not_active Expired - Lifetime
- 1999-06-24 DE DE69943292T patent/DE69943292D1/de not_active Expired - Lifetime
- 1999-06-24 JP JP11179056A patent/JP2000037194A/ja not_active Withdrawn
- 1999-06-24 EP EP99112181A patent/EP0971039B1/en not_active Expired - Lifetime
- 1999-11-12 US US09/439,594 patent/US6764821B1/en not_active Expired - Lifetime
-
2002
- 2002-11-22 US US10/303,152 patent/US20050260573A1/en not_active Abandoned
- 2002-11-22 US US10/304,035 patent/US7485417B2/en not_active Expired - Fee Related
- 2002-11-22 US US10/302,362 patent/US7264930B2/en not_active Expired - Lifetime
- 2002-11-27 US US10/307,108 patent/US8133989B2/en not_active Expired - Fee Related
- 2002-11-27 US US10/305,664 patent/US7713691B2/en not_active Expired - Lifetime
- 2002-11-27 US US10/305,690 patent/US7468245B2/en not_active Expired - Fee Related
- 2002-11-29 US US10/306,990 patent/US20030165938A1/en not_active Abandoned
-
2003
- 2003-12-24 JP JP2003428482A patent/JP4493330B2/ja not_active Expired - Lifetime
-
2005
- 2005-04-18 JP JP2005120409A patent/JP4675141B2/ja not_active Expired - Lifetime
-
2007
- 2007-10-26 US US11/925,556 patent/US8288092B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/925,730 patent/US8486633B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20030165939A1 (en) | 2003-09-04 |
| EP0971039A2 (en) | 2000-01-12 |
| US8133989B2 (en) | 2012-03-13 |
| US20030165938A1 (en) | 2003-09-04 |
| US20030170682A1 (en) | 2003-09-11 |
| EP0971039B1 (en) | 2011-03-23 |
| CA2273064A1 (en) | 1999-12-24 |
| IL130477A (en) | 2004-03-28 |
| JP4675141B2 (ja) | 2011-04-20 |
| JP2000037194A (ja) | 2000-02-08 |
| US8288092B2 (en) | 2012-10-16 |
| JP2005270108A (ja) | 2005-10-06 |
| JP4493330B2 (ja) | 2010-06-30 |
| US20030170681A1 (en) | 2003-09-11 |
| JP2004141170A (ja) | 2004-05-20 |
| US20090263789A1 (en) | 2009-10-22 |
| EP0971039A3 (en) | 2004-01-28 |
| US6764821B1 (en) | 2004-07-20 |
| US7468245B2 (en) | 2008-12-23 |
| US20090286285A1 (en) | 2009-11-19 |
| US20030165936A1 (en) | 2003-09-04 |
| US6743605B1 (en) | 2004-06-01 |
| DE69943292D1 (de) | 2011-05-05 |
| US20030104460A1 (en) | 2003-06-05 |
| US8486633B2 (en) | 2013-07-16 |
| US7264930B2 (en) | 2007-09-04 |
| US7713691B2 (en) | 2010-05-11 |
| US20050260573A1 (en) | 2005-11-24 |
| US7485417B2 (en) | 2009-02-03 |
| IL130477A0 (en) | 2000-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2273064C (en) | Novel processes for amplifying nucleic acid, post-termination labeling process for nucleic acid sequencing and producing nucleic acid having decreased thermodynamic stability | |
| US5942609A (en) | Ligation assembly and detection of polynucleotides on solid-support | |
| AU764099B2 (en) | Polynucleotide sequencing method | |
| JP3867926B2 (ja) | 核酸の増幅法 | |
| EP2049682A2 (en) | Method of library preparation avoiding the formation of adaptor dimers | |
| JP2003507024A (ja) | Ｐｎａ−ｄｎａキメラの３’末端でのポリメラーゼ伸長 | |
| EP1590482B1 (en) | Nucleic acid amplification using non-standard bases | |
| US8445664B2 (en) | Kits for amplifying and detecting nucleic acid sequences | |
| CA2475018C (en) | Novel processes for amplifying nucleic acid, post-termination labeling process for nucleic acid sequencing and producing nucleic acid having decreased thermodynamic stability | |
| IL152261A (en) | Process for non-linearly amplifying a nucleic acid sequence | |
| WO2005073409A2 (en) | Methods, compositions, and kits for amplifying and sequencing polynucleotides | |
| JPH05211873A (ja) | 核酸鋳型の特異的増殖方法および核酸の決定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20190617 |